Nucana plc announces results from two of clinical stage protides, nuc-3373 and nuc-7738

Nucana plc announced results from two of its clinical stage protides, nuc-3373 and nuc-7738, at the aacr-nci-eortc international conference on molecular targets and cancer therapeutics in boston, massachusetts. nucana presented interim data from the phase ib nutide:302 study in patients with advanced colorectal cancer confirming the previously reported favorable pharmacokinetic profile of nuc-3373. the anti-cancer mechanism of action of nuc-3373 has been previously observed in non-clinical studies, which nucana believes further supports the biological advantages of nuc-3373 over 5-fu. nuc-3373 is a protide transformation of 5-fluorouracil (5-fu), one of the most widely prescribed anti-cancer agents, and is currently being investigated in two clinical studies (nutide:301 and nutide:302). nuc-7738, nucana’s third protide to enter the clinic, is a transformation of 3’-deoxyadenosine (3’-da). six patients have received nuc-7738 to date in the phase i nutide:701 study. in non-clinical studies of nuc-7738, nucana has observed additional anti-cancer mechanisms of action to those previously reported for 3’da. significantly higher levels of anti-cancer metabolites are generated inside cancer cells than with 3’-da, causing increased cell injury. furthermore, the non-clinical data demonstrated that nuc-7738 activates ampk, which may inhibit the mtor pathway, resulting in further cancer cell death.
NCNA Ratings Summary
NCNA Quant Ranking